CLPT

In the past six months, ClearPoint Neuro's stock experienced a -16.29% change after reporting Q2 2026 results with increased revenue but a deeper net loss on August 3, 2026. On July 31, 2026, the stock increased by +2.95% following news of partner Aspen Neuroscience receiving FDA Regenerative Medicine Advanced Therapy (RMAT) Designation. The company announced Q2 2026 results on July 21, 2026, leading to a -2.47% change. Canadian approval for its Navigation System was announced on April 20, 2026. On September 29, 2026, the stock moved below its 50-day moving average, with negative Momentum Indicator and MACD, suggesting a potential downward trend. Overall, CLPT trended up by 14.39% in the past six months but lost 64.6% in the past year, closing at $10.49 on October 8, 2026.